Drug intelligence / Profile preview

tinidazole + lactobacillus acidophilus

Development stage
Unknown
Lead developer
Second Hospital of Shandong University
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral, Topical
01

Overview

Dizoltec + Yijunsheng is a combination therapeutic regimen used for the treatment of vaginitis, particularly bacterial vaginosis and mixed vaginal infections. Dizoltec is a brand name for tinidazole, a second-generation nitroimidazole antibiotic. It works by diffusing into the cells of anaerobic bacteria and protozoa, where its nitro group is reduced to active free radicals that cause DNA strand breakage and inhibit further DNA synthesis, leading to cell death. Yijunsheng is a probiotic preparation containing live Lactobacillus acidophilus. When administered vaginally, it restores the normal physiological flora of the vagina, which is often depleted during infection or antibiotic therapy. By replenishing beneficial lactobacilli, Yijunsheng helps maintain an acidic vaginal pH and produces inhibitory substances like hydrogen peroxide and lactic acid, which prevent the overgrowth of pathogenic organisms and reduce the rate of recurrence. This dual approach combines rapid pathogen eradication with the restoration of the vaginal microenvironment.

Other names
tinidazole and lactobacillus acidophilus combination
02

Targets

DNA

Beyond the preview

Go deeper on tinidazole + lactobacillus acidophilus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tinidazole + lactobacillus acidophilus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call